Study on Lorigerlimab for Treating Advanced Solid Tumors

Inclusion Criteria

• Have a confirmed diagnosis of high-grade serous ovarian cancer or clear cell gynecologic cancer that is resistant to platinum-based chemotherapy.
• Have persistent or returning cancer with documented progression.
• For ovarian cancer, must have had 1 to 3 previous treatments.
• For clear cell gynecologic cancer, must have had at least 1 previous treatment.
• If you have a BRCA mutation, you must have tried a PARP inhibitor if available and experienced progression or intolerance.
• Have at least one measurable tumor.
• Be willing to provide a tumor sample for testing.
• Be in good physical condition with acceptable lab results.
• Agree to use effective birth control if of childbearing potential.
• Must not be pregnant, planning to become pregnant, or breastfeeding.

Exclusion Criteria

• Have any medical or psychiatric condition that affects your ability to participate in the study.
• Have cancer that did not respond to initial platinum-based chemotherapy or progressed within 3 months of treatment.
• Have previously been treated with a checkpoint inhibitor.
• Have active cancer spread to the brain or spinal fluid.
• Have had a stem cell, tissue, or organ transplant.
• Have another cancer that was treated within the last 3 years, except for certain low-risk cancers like controlled skin cancer or carcinoma in situ.